Biotech Values

[DewDiligence]

You’re right—ABT’s PR on the Facet deal says ABT-888 complemented Facet’s oncology pipeline, not that it was part of it. My bad. As far as I can tell, ABT-888 was discovered by ABT’s own scientists, although NCI played a role in the early development (e.g. #msg-36995841).

I was surprised to hear ABT’s management say on today’s CC that the phase-2 trial in melanoma is “potentially registrational.”